MNPR

Monopar Therapeutics Inc.

0.96 USD
+0.09 (+10.81%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Monopar Therapeutics Inc. stock is up 55.58% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 June’s closed higher than May.

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc. engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.